CN1634197A - Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease - Google Patents
Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1634197A CN1634197A CN 200310122035 CN200310122035A CN1634197A CN 1634197 A CN1634197 A CN 1634197A CN 200310122035 CN200310122035 CN 200310122035 CN 200310122035 A CN200310122035 A CN 200310122035A CN 1634197 A CN1634197 A CN 1634197A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- scorpio
- radix ginseng
- paeoniae rubra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims description 131
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 38
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 18
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 14
- 208000026106 cerebrovascular disease Diseases 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 66
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 241000208340 Araliaceae Species 0.000 claims description 103
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 103
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 103
- 235000008434 ginseng Nutrition 0.000 claims description 103
- 241000522620 Scorpio Species 0.000 claims description 62
- 239000009490 scorpio Substances 0.000 claims description 62
- 241000237903 Hirudo Species 0.000 claims description 57
- 241000131808 Scolopendra Species 0.000 claims description 51
- 241001489978 Eupolyphaga Species 0.000 claims description 50
- 241000717739 Boswellia sacra Species 0.000 claims description 46
- 239000004863 Frankincense Substances 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 35
- 210000000582 semen Anatomy 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 23
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000931705 Cicada Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241001481692 Mesobuthus martensii Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000020061 kirsch Nutrition 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 40
- 238000002156 mixing Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 29
- 239000000796 flavoring agent Substances 0.000 description 28
- 235000019634 flavors Nutrition 0.000 description 28
- 208000025870 aspirin resistance Diseases 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 239000000341 volatile oil Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 239000007788 liquid Substances 0.000 description 18
- 239000000284 extract Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- 230000001476 alcoholic effect Effects 0.000 description 14
- 238000000643 oven drying Methods 0.000 description 14
- 235000019640 taste Nutrition 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 238000005303 weighing Methods 0.000 description 14
- 238000001035 drying Methods 0.000 description 12
- 239000007921 spray Substances 0.000 description 12
- 238000006356 dehydrogenation reaction Methods 0.000 description 11
- 238000011010 flushing procedure Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000005498 polishing Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940006607 hirudin Drugs 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 102000007625 Hirudins Human genes 0.000 description 4
- 108010007267 Hirudins Proteins 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 4
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 3
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition and its preparation process, wherein the composition comprises gen-seng, leeches, buthus martensi kirsch, wood louse, centipede, cicada shell, radix paeoniae rubrathe, borneol. The pharmacodynamics experiment shows that, the pharmaceutical composition has the function of improving acylpyrin resistance.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the application of a kind of pharmaceutical composition in the preparation resistant medication anti aspirin.
Background technology
Aspirin belongs to NSAID (non-steroidal anti-inflammatory drug), is a kind of effective antipyretic-antalgic anti-inflammatory agent, and its mechanism of action is suppress prostaglandin synthetic, and the modal side effect of this medicine is a gastrointestinal reaction, as inappetence, ulcer, even perforation; Anaphylaxis; Also have acute renal failure, chronic interstitial nephritis etc.Along with going deep into that aspirin is studied, the indication of aspirin also is extended to the treatment and the secondary prevention of cerebral arteriosclerosis, coronary heart disease, myocardial infarction by treatment heating, slight headache, toothache, neuralgia, arthralgia, myalgia and dysmenorrhea to medium degree, rheumatism etc.At present, aspirin is widely used in the treatment of cardiovascular and cerebrovascular disease, and its mechanism of action is aspirin thromboxane A capable of blocking in vivo
2(TXA
2) formation, TXA
2Can promote hematoblastic sticking and blood coagulation, thereby anticoagulant reduces the generation of arteriosclerosis, myocardial infarction, but discovers that groups of people can not effectively stop thromboxane A after taking aspirin
2Synthetic, promptly aspirin has lost the protective effect to cardio-cerebrovascular, this phenomenon is called aspirin resistance.Concerning Most patients, aspirin can make cardiovascular danger reduce by 25%, but the patient of aspirin resistance uses the aspirin for treatment cardiovascular and cerebrovascular disease, not only can not prevent the generation of cardiovascular event, can increase the incidence rate of heart infarction and apoplexy on the contrary, these find the use of restriction aspirin.To the research of aspirin resistance, adopt immune enzyme linked immunosorbent assay to measure the patient provides medication preceding urine sample more, is used for analyzing 11-dehydrogenation thromboxance B at present
2(TXB
2), 11-dehydrogenation thromboxance B
2It is thromboxane A
2Metabolite, high-caliber 11-dehydrogenation TXB in the urine
2Can differentiate whether the patient exists aspirin resistance, and whether medicine have the aspirin resistance of alleviating effect, the present invention finishes just on this basis.
The Chinese medicine blood-regulating drug, particularly the blood-activating stasis-removing kind medicine is the medicine that ancient Chinese medicine doctor is used always, this class medicine has the effect of promoting blood flow to regulate menstruation, removing blood stasis Xiao Disorder, blood-activating analgetic, detumescence and promoting granulation, modern pharmacology confirms, blood-regulating drug has the expansion coronary artery, increases coronary flow, reduce myocardial oxygen consumption, reduce peripheral vascular resistance, anticoagulant, microcirculation improvement, suppress thrombosis, fortifying fibre protein dissolution activity, anticoagulation system, microcirculation improvement, effects such as smooth muscle spasm are alleviated in blood pressure lowering.The clinical effect of Rhizoma Chuanxiong in the blood-regulating drug, Radix Salviae Miltiorrhizae, Herba Leonuri, Semen Persicae, Flos Carthami, Hirudo etc. is constantly expanded, and particularly the research of Hirudo is particularly outstanding, and its clinical practice is constantly expanded.
Hirudo is a kind famous and precious animal Chinese crude drug, records in the Ancient Times in China medical book and utilizes Hirudo (Hirudo) to treat multiple disease, in Shennong's Herbal, call its " main by stagnant blood, blood stasis, month close, the removing blood stasis removing food stagnancy is poly-... ".Cure its eliminating pathogenic factor for supporting vital QI of holy Zhang Zhongjing, the disease of treatment " blood stasis ", " water knot " has shown the curative effect that it is unique.Later age, Zhang Xichun praised this medicine: " deposit blood stasis and do not hinder fresh blood, the elite of pure lines water generates, and is at all harmless in edema caused by disorder of QI, and blood stasis is silently in invisible, and true good medicine also ".Modern medicine confirms, contains a kind of tart active substance---hirudin in the Hirudo saliva, and it is actually plants the polypeptides matter of being made up of aminoacid, and the polypide hirudin after dry the process of preparing Chinese medicine goes to pot, but also keeps heparin and antithrombotic element.Hirudin active extremely strong, extremely Wei Liang composition just can suppress the activity of thrombin in the blood, and has the effect of blood viscosity lowering, is widely used as anticoagulant clinically; In addition, hirudin also has the function that blood vessel dilating, alleviating vascular smooth muscle spasm and promotion absorb exudate, can treat apoplexy, amenorrhea, paraplegia, angina pectoris, nameless gall, tumor, neck lymph through diseases such as nuclears, hirudin can make transplant operation posterior vein blood vessel keep unimpeded.
Find that through the secular clinical research inventor traditional Chinese medical science thinks that the etiology and pathology of coronary heart disease is many because " imbalance of YIN and YANG, mechanism of qi be contrary to cause disorderly that the painstaking effort stasis of blood stagnates, blockage of the cardiac vessels, stagnation of QI and blood may bring about pain "." element is asked a numbness opinion piece of writing " meaning: " obstruction of heart-QI person; arteries and veins is obstructed ", in view of the above as seen, qi depression to blood stasis is the main traditional Chinese medical science pathologic basis of coronary heart disease, because gas and blood are the sources of human life activity's energy, the pathological change of all diseases relates to the QI and blood problem invariably, influences each other and mutual dependence for existence between gas and the blood, so " the capable then blood of gas is capable; the stagnation of QI is blood stasis then " arranged, " qi as the commander of blood, the operation of blood must rely on the promotion of gas ", thereby benefiting QI for activating blood circulation, removing obstruction in the collateral to relieve pain are when being the Chinese traditional treatment thoracic obstruction, pained fundamentum.
According to mentioned above principle, chosen Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Olibanum, Semen Ziziphi Spinosae etc. by the people and formed pharmaceutical composition.The result shows that it has the effect of benefiting QI for activating blood circulation, removing obstruction in the collateral to relieve pain.Be mainly used in weary, the blood stasis network resistance person of angina pectoris card genus insufficiency of heart-QI at present.Disease sees that chest feels oppressed, and twinge, angor, does not fixingly move cardiopalmus spontaneous perspiration, shortness of breath and fatigue, purplish tongue or ecchymosis is arranged, thready and hesitant pulse or knot generation.Also be used for blood stasis due to qi deficiency network resistance type apoplexy, disease is seen hemiplegia or hemianesthesia, crooked mouth and tongue, the unfavorable treatment that waits disease of speech.Modern pharmacological research proves that this pharmaceutical composition can obviously alleviate the acute myocardial ischemia degree, dwindles the myocardial ischemia scope, reduce the myocardial infarction zone, with coronary blood flow increasing, dilating coronary blood vessel, when strengthening the work done of left chamber, do not increase myocardial oxygen consumption, can adjust and improve cardiac function.In the experiment of rat local cerebral ischemia, this pharmaceutical composition can dwindle cerebral infarct volume, and can reduce cholesterol and the low density lipoprotein, LDL of high fat rat, blood viscosity lowering.
But the treatment that relevant this pharmaceutical composition has anti-aspirin resistance effect and is used for the aspirin resistance patient does not appear in the newspapers as yet, and the present invention studies resulting just on this basis.
Summary of the invention
The object of the present invention is to provide the application of a kind of pharmaceutical composition in the medicine of the anti-aspirin resistance of preparation particularly to provide the application of a kind of pharmaceutical composition in preparation treatment aspirin repellency cardiovascular disease medicine.
The said aspirin resistance of the present invention can not effectively stop thromboxane A after being meant and taking aspirin
2Synthetic, promptly aspirin has lost the protective effect to cardio-cerebrovascular, this phenomenon is referred to as aspirin resistance.Concerning Most patients, aspirin can make cardiovascular danger reduce by 25%, but the patient of aspirin resistance uses the aspirin for treatment cardiovascular disease, can not prevent the generation of cardiovascular event, can increase the incidence rate of heart infarction and apoplexy on the contrary, these find the use of restriction aspirin.Therefore, these cardiovascular disease are referred to as aspirin repellency cardiovascular disease in the middle of the present invention, particularly refer to coronary heart disease, the angina pectoris of using aspirin for treatment invalid.The present invention will be referred to as the medicine of anti-aspirin resistance to the medicine that aspirin repellency cardiovascular disease has a therapeutical effect, and this therapeutical effect is referred to as anti-aspirin resistance effect.
Under the situation that the cardiovascular disease incidence rate remains high at present, how can more effective treatment and prevention cardiovascular and cerebrovascular disease, it is very important thing, clinical aspirin commonly used is in the process of treatment and prevention cardiovascular and cerebrovascular disease, the aspirin resistance phenomenon occurred, the inventor is just under this prerequisite condition, to the medicine that is used for the treatment of cardiovascular and cerebrovascular disease commonly used at present, particularly Chinese medicine or compositions are screened, and find a kind of medicine that is used for anti-aspirin resistance.Pharmaceutical composition of the present invention through clinical observation under doses separately or the associating aspirin use together, can obviously improve " aspirin resistance " patient's symptom.The result shows that the former pharmaceutical composition of the present invention that is used for the treatment of coronary heart disease, angina pectoris, myocardial ischemia has the effect of anti-" aspirin resistance ".
Following drug component of the present invention is formed, consumption all has the low anti-curative effect of anti-preferably aspirin: the composition of compositions comprises Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum, and its consumption proportion is: Radix Ginseng 3～20 grams, Hirudo 3～30 grams, Eupolyphaga Seu Steleophaga 5～20 grams, Radix Paeoniae Rubra 3～15 grams, Scorpio 3～20 grams, Periostracum Cicadae 3～20 grams, Scolopendra 1～15 gram, Borneolum Syntheticum 1～20 gram.
The component of said composition can also be: Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Olibanum, Semen Ziziphi Spinosae; Preferred each amounts of components proportioning is: Radix Ginseng 3～10 grams, Hirudo 3～11 grams, Eupolyphaga Seu Steleophaga 5～10 grams, Olibanum (processed) 1～5 gram, Radix Paeoniae Rubra 3～9 grams, Lignum Dalbergiae Odoriferae 1～5 gram, Lignum Santali Albi 1～5 gram, Scorpio 3～9 grams, Periostracum Cicadae 3～12 grams, Scolopendra 1～3 gram, Borneolum Syntheticum 1～7 gram, Semen Ziziphi Spinosae (parched) 3～10 grams; Each best amounts of components is: Radix Ginseng 6 grams, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams; Or Radix Ginseng 10 restrains, Hirudo 8 restrains, Eupolyphaga Seu Steleophaga 7 restrains, Olibanum (processed) 2 restrains, Radix Paeoniae Rubra 5 restrains, Lignum Dalbergiae Odoriferae 2 restrains, Lignum Santali Albi 2 restrains, Scorpio 9 restrains, Periostracum Cicadae 7 restrains, Scolopendra 1 restrains, Borneolum Syntheticum 5 restrains, Semen Ziziphi Spinosae (parched) 5 restrains; Or Radix Ginseng 6 restrains, Hirudo 11 restrains, Eupolyphaga Seu Steleophaga 7 restrains, Olibanum (processed) 2 restrains, Radix Paeoniae Rubra 5 restrains, Lignum Dalbergiae Odoriferae 2 restrains, Lignum Santali Albi 2 restrains, Scorpio 3 restrains, Periostracum Cicadae 7 restrains, Scolopendra 1 restrains, Borneolum Syntheticum 5 restrains, Semen Ziziphi Spinosae (parched) 5 restrains; Or Radix Ginseng 5 restrains, Hirudo 10 restrains, Eupolyphaga Seu Steleophaga 7 restrains, Olibanum (processed) 2 restrains, Radix Paeoniae Rubra 5 restrains, Lignum Dalbergiae Odoriferae 2 restrains, Lignum Santali Albi 2 restrains, Scorpio 7 restrains, Periostracum Cicadae 3 restrains, Scolopendra 1 restrains, Borneolum Syntheticum 5 restrains, Semen Ziziphi Spinosae (parched) 5 restrains; Or Radix Ginseng 5.5 restrains, Hirudo 10.375 restrains, Eupolyphaga Seu Steleophaga 6.875 restrains, Olibanum (processed) 2.25 restrains, Radix Paeoniae Rubra 4.75 restrains, Lignum Dalbergiae Odoriferae 2.25 restrains, Lignum Santali Albi 2.25 restrains, Scorpio 6.875 restrains, Periostracum Cicadae 6.875 restrains, Scolopendra 1.375 restrains, Borneolum Syntheticum 1.375 restrains, Semen Ziziphi Spinosae (parched) 4.625 restrains.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method.The preparation of effective ingredient of the present invention can be adopted following method: water extraction, decoction and alcohol sedimentation technique, extraction, infusion process, percolation, reflux extraction, continuous backflow extraction method, macroreticular resin absorbing method preparation.For example, these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably adopt following technology to extract, but this can not limit protection scope of the present invention to raw material in order to make each crude drug of this medicine bring into play drug effect better.
Preparation of drug combination method of the present invention is as follows:
(a) it is standby to get Scolopendra, Scorpio, Radix Ginseng, Hirudo, Eupolyphaga Seu Steleophaga, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum;
(b) above eight flavor medicines such as Radix Ginseng are cleaned, the independent porphyrize of Borneolum Syntheticum wherein; With Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, this five tastes animal kind medicine washing of Periostracum Cicadae, oven drying at low temperature is ground into fine powder by broken make and break after its proportioning weighing in pulverizing together:
(c) with Radix Ginseng alcoholic solution reflux, extract, twice, merge extractive liquid, reclaims ethanol and does not distinguish the flavor of to there being alcohol, and the Radix Ginseng residue is standby;
(d) Radix Paeoniae Rubra is joined in the residue and aqueous solution of Radix Ginseng, add entry, heating decocts secondary, collecting decoction, concentrate clear paste, add the panaxynol extracting solution then, mixing is ground into fine powder;
(e) Borneolum Syntheticum and animal kind medicine bedding-in is even, with extract powder mixing such as Radix Paeoniae Rubra, add appropriate amount of auxiliary materials again, incapsulate, promptly.
Preferred manufacturing procedure is:
(a) it is standby to get Radix Ginseng 3～20 gram, Hirudo 3～30 grams, Eupolyphaga Seu Steleophaga 5～20 grams, Radix Paeoniae Rubra 3～15 grams, Scorpio 3～20 grams, Periostracum Cicadae 3～20 grams, Scolopendra 1～15 gram, Borneolum Syntheticum 1～20 gram;
(b) above eight flavor medicines such as Radix Ginseng are cleaned, the independent porphyrize of Borneolum Syntheticum wherein; With Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, this five tastes animal kind medicine washing of Periostracum Cicadae, oven drying at low temperature is ground into fine powder by broken make and break after its proportioning weighing in pulverizing together:
(c) be 70% alcoholic solution reflux, extract, twice with Radix Ginseng with the concentration of 6 times of amounts, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, and the Radix Ginseng residue is standby;
(d) Radix Paeoniae Rubra is joined in the residue and aqueous solution of Radix Ginseng, the water that adds 9 times of crude drug total amounts, heating decocts secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction, be concentrated into relative density and be the clear paste of 1.20-1.26 gram/cubic centimetre (60 ℃ time record), add the panaxynol extracting solution then, mixing, dry under 60 ℃ of-70 ℃ of conditions, be ground into fine powder;
(e) Borneolum Syntheticum and animal kind medicine bedding-in is even, with extract powder mixing such as Radix Paeoniae Rubra, add appropriate amount of auxiliary materials again, incapsulate, promptly get medicine of the present invention.
Another preparation of drug combination method of the present invention:
(a) it is standby to get Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Olibanum, Semen Ziziphi Spinosae;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and its residue and aqueous solution are standby.Radix Ginseng alcoholic solution reflux, extract, 2 times, merge extractive liquid, reclaims ethanol and does not distinguish the flavor of to there being alcohol, Radix Ginseng residue and Lignum Santali Albi, the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicine such as Radix Ginseng, add entry, and heating decocts secondary, collecting decoction, concentrate clear paste, add the Radix Ginseng extractive solution then, mixing is put into baking oven, drying is ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes capsule, promptly gets medicine of the present invention.
The aforementioned pharmaceutical compositions preferred manufacturing procedure is as follows:
(a) it is standby to get Radix Ginseng 3～10 gram, Hirudo 3～11 grams, Eupolyphaga Seu Steleophaga 5～10 grams, Olibanum (processed) 1～5 gram, Radix Paeoniae Rubra 3～9 grams, Lignum Dalbergiae Odoriferae 1～5 gram, Lignum Santali Albi 1～5 gram, Scorpio 3～9 grams, Periostracum Cicadae 3～12 grams, Scolopendra 1～3 gram, Borneolum Syntheticum 1～7 gram, Semen Ziziphi Spinosae (parched) 3～10 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes capsule, promptly gets medicine of the present invention.
The best preparation method of aforementioned pharmaceutical compositions is as follows:
(a) it is standby to get Radix Ginseng 5.5 gram, Hirudo 10.375 grams, Eupolyphaga Seu Steleophaga 6.875 grams, Olibanum (processed) 2.25 grams, Radix Paeoniae Rubra 4.75 grams, Lignum Dalbergiae Odoriferae 2.25 grams, Lignum Santali Albi 2.25 grams, Scorpio 6.875 grams, Periostracum Cicadae 6.875 grams, Scolopendra 1.375 grams, Borneolum Syntheticum 1.375 grams, Semen Ziziphi Spinosae (parched) 4.625 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, promptly gets medicine of the present invention.
Pharmaceutical composition of the present invention can be made into common dosage form at present; Preferably make the oral formulations form, made dosage form can be: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ointment, plaster, spray, drop pill; Preferably capsule, tablet, electuary, powder, oral liquid formulations form.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
More than each single medicinal material, especially adjuvant drug, messenger drug or adjuvant drug and messenger drug in forming, can be replaced by suitable Chinese medicine individually or simultaneously with the identical property of medicine, effect, it is constant to replace back Chinese medicine preparation and drug effect thereof.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 time, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
In order to understand essence of the present invention better,, its new purposes in pharmaceutical field is described below by the result of the test of this pharmaceutical composition of clinical observation at anti-" aspirin resistance ".This test medication is to prepare by embodiment 1 method.
The present invention adopts the research method to aspirin resistance commonly used at present, uses immune enzyme linked immunosorbent assay mensuration patient urine sample is provided, and is used for analyzing 11-dehydrogenation thromboxance B
2(TXB
2) variation of level, 11-dehydrogenation thromboxance B
2It is thromboxane A
2Metabolite, high-caliber 11-dehydrogenation TXB in the urine
2Can differentiate whether the patient exists aspirin resistance, and whether medicine has the aspirin resistance of alleviating effect, to judge whether the patient has the effect that reduces aspirin resistance after taking medicine of the present invention, the present invention is by clinical research, prove the application of pharmaceutical composition of the present invention in the medicine of the anti-aspirin resistance of preparation, had the effect of anti-aspirin resistance.
Retrospective approach is adopted in this research: normal value with reference to Australia about the aspirin resistance result of study
Physical data
This organizes 178 routine patients all from the General Logistics Department first cadre's sanitarium, the eight cadre's sanitarium retired personnels of branch.Male 140 people wherein, women 38 people.70 years old～87 years old age, 77.1 years old mean age.Select 170 people at random and carry out the specimen detection, and data tolerance interval 150 people (IC20～IC80).Charge among the statistician clothes aspirin person 50 people; Take medicine 50 people of the present invention; Sharer 50 people (all patient took medicine more than half a year at least continuously to the day of sampling), wherein 91 people are associated with history of hypertension, and 25 people have hyperlipidemia, and 32 people have diabetes, and 139 people have coronary heart disease, and 57 people have cerebrovascular disease.
Materials and methods
Institute's urine sample of adopting is urina sanguinis stage casing for the first time, drop into immediately after getting in the liquid nitrogen, after be stored in-86 ℃ of cryogenic refrigerators standby.Use immune enzyme linked immunosorbent assay and detect 11-dehydrogenation TXB
2, test kit adopts Cayman Chemical company product, and all experiment is finished in the biological institute of sky scholar's power academy, and patient's packet conditions is carried out double blinding to lab assistant and later data statistician.
The result
Average between group is carried out the t-check, resistant's frequency between group is carried out x
2Check.
Table 1. is respectively organized patient's urine value 11-dehydrogenation TXB
2(ng/mmol)
Aspirin (n=50 example) medicine of the present invention (n=50 example) aspirin and drug combination of the present invention (n=50 example)
Urine value 11-dehydrogenation TXB
2(ng/mmol) urine value 11-dehydrogenation TXB
2(ng/mmol) urine value 11-dehydrogenation TXB
2(ng/mmol)
33.65 31.25 20.45
18.72 19.88 11.43
18.65 11.56 31.68
31.25 10.89 18.46
10.20 32.77 17.89
37.45 12.85 25.52
12.24 37.64 20.03
36.01 22.55 33.14
11.63 10.2 8.89
37.61 8.92 12.37
34.64 27.98 12.88
13.41 28.5 39.62
16.68 21.36 22.31
27.60 27.45 11.94
30.12 15.34 29.69
14.74 35.36 13.58
15.54 9.67 28.09
38.25 18.9 9.55
27.68 25.24 31.24
28.94 29.63 19.67
36.51 13.65 22.18
17.45 33.46 12.38
14.23 10.47 27.45
39.35 23.58 9.58
37.65 22.14 30.87
9.25 10.03 19.99
14.84 34.56 30.12
40.62 10.53 30.45
28.43 36.44 10.31
27.32 15.78 27.45
12.33 23.45 12.32
39.5 10.99 8.85
18.25 11.84 33.44
37.42 16.77 9.28
26.26 32.74 14.65
30.44 30.14 28.79
16.82 24.25 8.15
9.96 14.11 26.12
9.24 30.42 8.97
26.43 25.26 13.69
24.22 11.53 31.15
30.24 25.36 28.16
34.45 13.44 17.64
30.22 35.43 20.11
9.78 10.38 22.1
27.63 14.52 38.17
10.1 19.81 8.02
36.38 22.68 10.88
45.27 19.55 26.53
15.24 12.78 19.87
X±SD 25.02±10.67 21.08±8.87 20.52±8.99
Conclusion: by above-mentioned laboratory observation, when finding medicine of the present invention and aspirin share, use separately with aspirin to compare, obvious significant difference is arranged, t=2.28 p＜0.05 between the TXB2 excretion in urinating between two groups of groups; Use between medicine group of the present invention and aspirin group group separately and obvious significant difference is also arranged, t=2.01 p＜0.05 between the TXB2 excretion in the urine; No obvious significant difference between the TXB2 excretion in urinating between medicine group of the present invention and drug combination aspirin group group of the present invention, t=0.31 p＞0.05.
This experimental result proves that medicine of the present invention can make the TXB2 excretion in the urine reduce thromboxane A promptly capable of blocking in vivo
2(TXA
2) formation, reduce hematoblastic sticking and blood coagulation, thereby anticoagulant, reduce the generation of arteriosclerosis, myocardial infarction, presentation of results medicine of the present invention has anti-aspirin resistance effect, the cardiovascular patient invalid to aspirin, medicine of the present invention still has the effect that improves life index.
Medicine of the present invention is to be prepared from by following examples, the addition manner of dosage form of the present invention and relevant auxiliary materials is identical with the conventional formulation method with ratio, the preparation method of part embodiment is no longer enumerated at this, and following specific embodiment is an explanation of the invention, can not limit the present invention.
The specific embodiment
Embodiment 1:
(a) get Radix Ginseng 55.00g, Hirudo 103.75g, Scorpio 68.75g, Lignum Santali Albi 22.50gg, Eupolyphaga Seu Steleophaga 68.75g, Scolopendra 13.75g, Periostracum Cicadae 68.75g, Lignum Dalbergiae Odoriferae 22.50g, Radix Paeoniae Rubra 47.50g, Ziziphi Spinosae people (stir-fry) 46.25g, Olibanum (system) 22.50g, Borneolum Syntheticum 13.75g are standby;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 1000 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 2:
(a) get Scolopendra 3g, Scorpio 16g, Radix Ginseng 12g, Hirudo 24g, Eupolyphaga Seu Steleophaga 16g, Periostracum Cicadae 16g, Radix Paeoniae Rubra 11g, Borneolum Syntheticum 3g are standby;
(b) above eight flavor medicines such as Radix Ginseng are cleaned, the independent porphyrize of Borneolum Syntheticum wherein; With Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, this five tastes animal kind medicine washing of Periostracum Cicadae, oven drying at low temperature is ground into fine powder by broken make and break after its proportioning weighing in pulverizing together:
(c) be 70% alcoholic solution reflux, extract, twice with Radix Ginseng with the concentration of 6 times of amounts, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, and the Radix Ginseng residue is standby;
(d) Radix Paeoniae Rubra is joined in the residue and aqueous solution of Radix Ginseng, the water that adds 9 times of crude drug total amounts, heating decocts secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction, be concentrated into relative density and be the clear paste of 1.20-1.26 gram/cubic centimetre (60 ℃ time record), add the panaxynol extracting solution then, mixing, dry under 60 ℃ of-70 ℃ of conditions, be ground into fine powder;
(e) Borneolum Syntheticum and animal kind medicine bedding-in is even, with extract powder mixing such as Radix Paeoniae Rubra, add appropriate amount of auxiliary materials again, incapsulate, promptly get medicine of the present invention.
Embodiment 3:
(a) it is standby to get Radix Ginseng 6 gram, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 4:
(a) it is standby to get Radix Ginseng 10 gram, Hirudo 8 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 9 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 5:
(a) it is standby to get Radix Ginseng 6 gram, Hirudo 11 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 3 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 6:
(a) it is standby to get Radix Ginseng 5 gram, the Radix Astragali 3 grams, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 3 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 9 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 7:
(a) it is standby to get Radix Ginseng 3 gram, Hirudo 3 grams, Eupolyphaga Seu Steleophaga 5 grams, Olibanum (processed) 1 gram, Radix Paeoniae Rubra 3 grams, Lignum Dalbergiae Odoriferae 1 gram, Lignum Santali Albi 1 gram, Scorpio 9 grams, Periostracum Cicadae 3 grams, Scolopendra 3 grams, Borneolum Syntheticum 1 gram, Semen Ziziphi Spinosae (parched) 10 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 75% alcoholic solution reflux, extract, of 8 times of amounts 2 times, and 4 hours for the first time, 1 hour for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 8 times of water gagings, heating decocts secondary, 3.5 hours for the first time, 1.5 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.10～1.25 (50 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 50～80 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 8:
(a) it is standby to get Radix Ginseng 10 gram, Hirudo 11 grams, Eupolyphaga Seu Steleophaga 10 grams, Olibanum (processed) 5 grams, Radix Paeoniae Rubra 3 grams, Lignum Dalbergiae Odoriferae 5 grams, Lignum Santali Albi 4 grams, Scorpio 8 grams, Periostracum Cicadae 10 grams, Scolopendra 2 grams, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 8 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 72% alcoholic solution reflux, extract, of 5 times of amounts 2 times, and 2.5 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 7 times of water gagings, heating decocts secondary, 2 hours for the first time, 1 hour for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.15～1.20 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 9:
(a) it is standby to get Radix Ginseng 6.5 gram, Hirudo 5.5 grams, Eupolyphaga Seu Steleophaga 6.5 grams, Olibanum (processed) 2.5 grams, Radix Paeoniae Rubra 3.8 grams, Lignum Dalbergiae Odoriferae 4.8 grams, Lignum Santali Albi 1.5 grams, Scorpio 4.5 grams, Periostracum Cicadae 10 grams, Scolopendra 2.3 grams, Borneolum Syntheticum 1.7 grams, Semen Ziziphi Spinosae (parched) 6 grams;
(b) above 12 flavor medicines clean respectively, five tastes animal kind medicines such as Scorpio, and washing is taken out, and puts into drying baker, and oven drying at low temperature is standby, and is by the prescription weighing, cataclasm as one sees fit.Lignum Santali Albi, Lignum Dalbergiae Odoriferae are extracted volatile oil, and oil yield is no less than 1%, and its residue and aqueous solution are standby; Radix Ginseng is with 70% alcoholic solution reflux, extract, of 6 times of amounts 2 times, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng residue and Lignum Santali Albi, and the residue of Lignum Dalbergiae Odoriferae merges, and is standby; Radix Paeoniae Rubra, Ziziphi Spinosae people join in the residue and aqueous solution of medicines such as Radix Ginseng, add 10 times of water gagings, heating decocts secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, being concentrated into relative density is the clear paste of 1.20～1.25 (60 ℃ of heat are surveyed), adds the Radix Ginseng extractive solution then, mixing, put into baking oven, dry under 60～70 ℃ of conditions, be ground into fine powder; Olibanum and animal kind medicine flushing are ground into fine powder; The independent porphyrize of Borneolum Syntheticum, even with animal kind medicine thing facing-up, pulverize mixing with extractum such as Radix Paeoniae Rubra again, spray into volatile oil, mixing incapsulates close lid half an hour, makes 100 capsules, with polishing of capsules, packing dress box, promptly.
Embodiment 10:
Get Radix Ginseng 6 gram, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, { two (stir-fry) 5 restrains standby Ziziphi Spinosae;
Preparation method is with embodiment 1.
Embodiment 11:
Getting Radix Codonopsis 3 gram, Hirudo 5 grams, Eupolyphaga Seu Steleophaga 5 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 5 grams, Periostracum Cicadae 4 grams, Scolopendra 0.5 gram, Borneolum Syntheticum 3 grams, Semen Ziziphi Spinosae (stir-fry) 5 restrains standby;
Preparation method is with embodiment 1.
Embodiment 12:
Get Radix Pseudostellariae 5 gram, Radix Salviae Miltiorrhizae 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, { two (stir-fry) 5 restrains standby Ziziphi Spinosae;
Preparation method is with embodiment 1.
Embodiment 13:
Get Radix Ginseng 5 gram, the Radix Astragali 3 grams, Hirudo 10 grams, worker Trionyx sinensis Wiegmann worm 7 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 3 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, { two (stir-fry) 5 restrains standby Ziziphi Spinosae;
Preparation method is with embodiment 1.
Embodiment 14:
Getting Radix Ginseng 10 gram, Hirudo 3 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (system) 2 grams, Scorpio 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 restrains standby;
Preparation method is with embodiment 2.
Embodiment 15:
Get Radix Ginseng 6 gram, Hirudo 11 grams, Olibanum (system) 2 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, { two (stir-fry) 5 restrains standby Ziziphi Spinosae;
Preparation method is with embodiment 2.
Embodiment 16:
Getting Radix Ginseng 3 gram, Hirudo 3 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (stir-frys) 5 restrains standby;
Preparation method is with embodiment 1.
Embodiment 17:
Getting Radix Ginseng 10 gram, Hirudo 8 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 9 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (stir-fry) 5 restrains standby;
Preparation method is with embodiment 1.
Embodiment 18:
Getting Radix Ginseng 6 gram, Hirudo 11 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (system) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 3 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (stir-fry) 5 restrains standby;
Preparation method is with embodiment 1.
Embodiment 19:
It is standby to get Radix Ginseng 10 gram, Hirudo 11 grams, Eupolyphaga Seu Steleophaga 7 grams, Radix Paeoniae Rubra 5 grams, Scorpio 9 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams; 2.
Embodiment 20:
It is standby to get Radix Ginseng 5 gram, Hirudo 8 grams, Eupolyphaga Seu Steleophaga 4 grams, Radix Paeoniae Rubra 2 grams, Scorpio 6 grams, Periostracum Cicadae 3 grams, Scolopendra 2 grams, Borneolum Syntheticum 1 gram;
Preparation method is with embodiment 2.
Embodiment 21:
It is standby to get Radix Ginseng 9 gram, Hirudo 4 grams, Eupolyphaga Seu Steleophaga 6 grams, Radix Paeoniae Rubra 7 grams, Scorpio 5 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 2 grams, Radix Salviae Miltiorrhizae 12 grams;
Preparation method is with embodiment 2.
Embodiment 22:
It is standby to get Radix Ginseng 12 gram, Hirudo 7 grams, Eupolyphaga Seu Steleophaga 3 grams, Radix Paeoniae Rubra 7 grams, Scorpio 4.5 grams, Periostracum Cicadae 5.5 grams, Scolopendra 4 grams, Borneolum Syntheticum 3 grams, Radix Salviae Miltiorrhizae 12 grams, Radix Notoginseng 10 grams;
Preparation method is with embodiment 1.
Embodiment 23:
It is standby to get Radix Ginseng 15 gram, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Radix Paeoniae Rubra 12 grams, Scorpio 11 grams, Periostracum Cicadae 8 grams, Scolopendra 10 grams, Borneolum Syntheticum 5 grams, Radix Salviae Miltiorrhizae 14 grams, Radix Notoginseng 14 grams, the Radix Astragali 15 grams;
Preparation method is with embodiment 1.
Embodiment 24:
It is standby to get Radix Ginseng 20 gram, Hirudo 30 grams, Eupolyphaga Seu Steleophaga 15 grams, Radix Paeoniae Rubra 15 grams, Scorpio 10 grams, Periostracum Cicadae 20 grams, Scolopendra 15 grams, Borneolum Syntheticum 6 grams;
Preparation method is with embodiment 2.
Embodiment 25:
It is standby to get Radix Ginseng 15 gram, Hirudo 20 grams, Eupolyphaga Seu Steleophaga 20 grams, Radix Paeoniae Rubra 10 grams, Scorpio 20 grams, Periostracum Cicadae 15 grams, Scolopendra 10 grams, Borneolum Syntheticum 10 grams;
Preparation method is with embodiment 2.
Claims (14)
1, the application of a kind of pharmaceutical composition in the low medicine that resists of the anti-aspirin of preparation, wherein the composition of said composition comprises: Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum.
2, purposes as claimed in claim 1, wherein the consumption proportion of each component is: Radix Ginseng 3～20 grams, Hirudo 3～30 grams, Eupolyphaga Seu Steleophaga 5～20 grams, Radix Paeoniae Rubra 3～15 grams, Scorpio 3～20 grams, Periostracum Cicadae 3～20 grams, Scolopendra 1～15 gram, Borneolum Syntheticum 1～20 gram.
3, purposes as claimed in claim 1, wherein the composition of said composition comprises: Radix Ginseng, Hirudo, Scorpio, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Olibanum, Semen Ziziphi Spinosae.
4, purposes as claimed in claim 3, wherein the consumption proportion of each component is: Radix Ginseng 3～10 grams, Hirudo 3～11 grams, Eupolyphaga Seu Steleophaga 5～10 grams, Olibanum (processed) 1～5 gram, Radix Paeoniae Rubra 3～9 grams, Lignum Dalbergiae Odoriferae 1～5 gram, Lignum Santali Albi 1～5 gram, Scorpio 3～9 grams, Periostracum Cicadae 3～12 grams, Scolopendra 1～3 gram, Borneolum Syntheticum 1～7 gram, Semen Ziziphi Spinosae (parched) 3～10 grams.
5, purposes as claimed in claim 3, wherein the consumption proportion of each component is:
Radix Ginseng 6 grams, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams.
6, purposes as claimed in claim 3, wherein the consumption proportion of each component is:
Radix Ginseng 10 grams, Hirudo 8 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 9 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams.
7, purposes as claimed in claim 3, wherein the consumption proportion of each component is:
Radix Ginseng 6 grams, Hirudo 11 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 3 grams, Periostracum Cicadae 7 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams.
8, purposes as claimed in claim 3, wherein the consumption proportion of each component is:
Radix Ginseng 5 grams, the Radix Astragali 3 grams, Hirudo 10 grams, Eupolyphaga Seu Steleophaga 7 grams, Olibanum (processed) 2 grams, Radix Paeoniae Rubra 5 grams, Lignum Dalbergiae Odoriferae 2 grams, Lignum Santali Albi 2 grams, Scorpio 7 grams, Periostracum Cicadae 3 grams, Scolopendra 1 gram, Borneolum Syntheticum 5 grams, Semen Ziziphi Spinosae (parched) 5 grams.
9, purposes as claimed in claim 3, wherein the consumption proportion of each component is:
Radix Ginseng 5.5 grams, Hirudo 10.375 grams, Eupolyphaga Seu Steleophaga 6.875 grams, Olibanum (processed) 2.25 grams, Radix Paeoniae Rubra 4.75 grams, Lignum Dalbergiae Odoriferae 2.25 grams, Lignum Santali Albi 2.25 grams, Scorpio 6.875 grams, Periostracum Cicadae 6.875 grams, Scolopendra 1.375 grams, Borneolum Syntheticum 1.375 grams, Semen Ziziphi Spinosae (parched) 4.625 grams.
10,, it is characterized in that described compositions is the oral formulations form as any one described purposes in the claim 1～9.
11,, it is characterized in that described compositions is a kind of of capsule, tablet, electuary, powder, oral liquid formulations form as any one described purposes in the claim 1～9.
12,, it is characterized in that the application of this pharmaceutical composition in the medicine of preparation treatment aspirin repellency cardiovascular and cerebrovascular disease as the described purposes of claim 1～9.
13, purposes as claimed in claim 12 is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant the invalid cardiovascular and cerebrovascular disease of use aspirin for treatment.
14,, it is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant invalid coronary heart disease, the angina pectoris of use aspirin for treatment as the said aspirin repellency cardiovascular and cerebrovascular disease of claim 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310122035 CN1634197A (en) | 2003-12-31 | 2003-12-31 | Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310122035 CN1634197A (en) | 2003-12-31 | 2003-12-31 | Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634197A true CN1634197A (en) | 2005-07-06 |
Family
ID=34844342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310122035 Pending CN1634197A (en) | 2003-12-31 | 2003-12-31 | Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634197A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632726B (en) * | 2008-07-21 | 2012-09-05 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization |
-
2003
- 2003-12-31 CN CN 200310122035 patent/CN1634197A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632726B (en) * | 2008-07-21 | 2012-09-05 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1545382A (en) | Method for processing ginseng and the uses of extract of processed ginseng | |
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1596920A (en) | Medicinal composition for treating cardiopathy and its preparation method and use | |
| EP2149379A1 (en) | Use of a vegetable drug composition in the manufacturing of a pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis | |
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1965966A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1565552A (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN100346817C (en) | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia | |
| CN1166382C (en) | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1289128C (en) | A pharmaceutical composition for treating headache disease and process and uses thereof | |
| CN1785307A (en) | Chinese medicine for treating mammary gland cystoma, mammitis and preparation method of its film coating | |
| CN1221280C (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1634197A (en) | Application of pharmaceutical composition in the process for preparing medicine for treating aspirin resistant cardiovascular and cerebrovascular disease | |
| CN1507352A (en) | Compound plant medicine and its application | |
| CN1903238A (en) | Extractive of traditional Chinese medicine, its prepns., preparing method and application thereof | |
| CN1300161C (en) | Yellow pigment of safflower preparation method and application | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1602939A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1162177C (en) | Medicine for curing fatty liver | |
| CN101053626A (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris and its preparation method | |
| CN1239170C (en) | Chinese patent drug for treating liver cancer | |
| CN1539474A (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN105853497A (en) | Preparation method of medicine for treating hypertension, coronary heart disease and coronary artery atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |